title: [Three cases of unresectable advanced gastric cancer treated with S-1 based chemotherapy after surgical bypass].
abstract: Case 1: The patient underwent gastrojejunostomy [T4 (pancreas), N2, P0, CY0] in April 2004, and then 23 courses of chemotherapy with S-1 + DOC (40 mg/m2/day 1:3 w). Then, the regimen was switched to CPT-11 because of a decreased efficacy of the treatment, and CPT-11 was continued for 10 courses. (The patient was alive for 36 months). Case 2: The patient was treated with S-1 [T4 (pancreas), N3, P0, CY0] after surgical bypass in November 2004. After two courses of chemotherapy with S-1, 9 courses of the second-line chemotherapy with PTX (120 mg/m2/day 1:3 w) were provided. As the disease progressed, 15 courses of CPT-11 (125 mg/m2/day 1: 2 w) were administered (The patient was alive for 29 months). Case 3: The patient was diagnosed as CY1 by staging laparoscopy in August 2005. The second-look laparoscopy revealed CY0 after 5 courses of S-1 + PTX (120 mg/m2/day1: 3 w). Although the second-look laparoscopy revealed CYO, gastrojejunostomy was performed because of P1 and T4 (pancreas). Chemotherapy with S-1 + PTX was continued for 18 courses, followed by OPT-11 (The patient was alive for 20 months). This report describes three cases of gastric cancer treated with S-1 based chemotherapy after surgical bypass, which resulted in the long-term survival and an improvement of the patients' quality of life.
authors.affiliation: Dept. of Surgery, Kansai Rousai Hospital.
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Tamura
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Miki
authors.forename: Kaoru
authors.initials: K
authors.lastname: Okada
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Miyake
authors.forename: Mio
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Kimiko
authors.initials: K
authors.lastname: Uji
authors.forename: Atsuko
authors.initials: A
authors.lastname: Yoshida
authors.forename: Rei
authors.initials: R
authors.lastname: Suzuki
authors.forename: Shin
authors.initials: S
authors.lastname: Nakahira
authors.forename: Ken
authors.initials: K
authors.lastname: Nakata
authors.forename: Chiyomi
authors.initials: C
authors.lastname: Egawa
authors.forename: Shu
authors.initials: S
authors.lastname: Okamura
authors.forename: Keishi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Takatsuka
mesh_terms: D000368:Aged; D004338:Drug Combinations; D005260:Female; D015390:Gastric Bypass; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid